載入...
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
BACKGROUND: Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver oncogene, BCR-ABL1, which is a constitutive tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the central treatment strategy for CML patients and have significantly improved survival rates, but the T...
Na minha lista:
| 發表在: | Ann Oncol |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4516045/ https://ncbi.nlm.nih.gov/pubmed/25712455 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv110 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|